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Abstract
Background: Already since the 1990s, promoter CpG island methylation markers have been considered promising
diagnostic, prognostic, and predictive cancer biomarkers. However, so far, only a limited number of DNA
methylation markers have been introduced into clinical practice. One reason why the vast majority of methylation
markers do not translate into clinical applications is lack of independent validation of methylation markers, often
caused by differences in methylation analysis techniques. We recently described RET promoter CpG island
methylation as a potential prognostic marker in stage II colorectal cancer (CRC) patients of two independent series.
Methods: In the current study, we analyzed the RET promoter CpG island methylation of 241 stage II colon
cancer patients by direct methylation-specific PCR (MSP), nested-MSP, pyrosequencing, and methylation-sensitive
high-resolution melting (MS-HRM). All primers were designed as close as possible to the same genomic region. In
order to investigate the effect of different DNA methylation assays on patient outcome, we assessed the clinical
sensitivity and specificity as well as the association of RET methylation with overall survival for three and five years of
follow-up.
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Results: Using direct-MSP and nested-MSP, 12.0 % (25/209) and 29.6 % (71/240) of the patients showed RET
promoter CpG island methylation. Methylation frequencies detected by pyrosequencing were related to the
threshold for positivity that defined RET methylation. Methylation frequencies obtained by pyrosequencing
(threshold for positivity at 20 %) and MS-HRM were 13.3 % (32/240) and 13.8 % (33/239), respectively. The
pyrosequencing threshold for positivity of 20 % showed the best correlation with MS-HRM and direct-MSP
results. Nested-MSP detected RET promoter CpG island methylation in deceased patients with a higher
sensitivity (33.1 %) compared to direct-MSP (10.7 %), pyrosequencing (14.4 %), and MS-HRM (15.4 %). While
RET methylation frequencies detected by nested-MSP, pyrosequencing, and MS-HRM varied, the prognostic
effect seemed similar (HR 1.74, 95 % CI 0.97–3.15; HR 1.85, 95 % CI 0.93–3.86; HR 1.83, 95 % CI 0.92–3.65,
respectively).
Conclusions: Our results show that upon optimizing and aligning four RET methylation assays with regard
to primer location and sensitivity, differences in methylation frequencies and clinical sensitivities are
observed; however, the effect on the marker’s prognostic outcome is minimal.
Keywords: DNA methylation, RET, Clinical sensitivity, Analytic sensitivity, MSP, pyrosequencing, MS-HRM
Background
DNA methylation has become an attractive target for bio-
marker research. It can be used as a marker for early detec-
tion of a disease or to predict prognosis or response to
therapy. Although many researchers focus on the identifica-
tion of novel methylation DNA markers and improvement
of sensitivity and specificity of markers, currently, the
applicability of methylation markers in the clinic is very
limited. Of the hundreds of putative methylation markers
reported in literature, only few are currently used in clinical
practice. NDRG4 and BMP3 promoter CpG island methyla-
tion analysis is part of the FDA-approved molecular marker
assay named Cologuard for early detection of colorectal
cancer (CRC) [1, 2]. SEPT9 is a blood-based alternative for
colorectal cancer diagnosis [3]. GSTP1, RASSF1, and APC
are part of a biopsy tissue-based, multiplex methylation-
specific PCR (MSP) assay for prostate cancer detection
[4, 5]. A urine-based DNA-methylation assay profiling
TWIST1 and NID2, in combination with non-epigenetic
markers, has shown to be useful for bladder cancer diagno-
sis in hematuria patients [6].
The absence of DNA methylation markers in clinical set-
tings is mainly due to an ill-powered marker identification
strategy in small selected series resulting in chance findings
and false-positive identification of biomarkers. In addition,
a lack of adequate validation of markers in independent
patient series generating a good level of evidence [7–9], and
the use of technologies with varying sensitivity and specifi-
city to analyze these markers, leads to discrepant results
[10, 11]. With the development of diverse DNA methyla-
tion analysis techniques, comparison of methylation data
has become more complex. Substantial variation in
frequency and clinical value of specific methylation markers
has been reported [12–14]. The same holds true for the fre-
quency of the CpG island methylator phenotype (CIMP).
The absence of a universal definition to define CIMP has
resulted in challenging interpretation of the data, as well as
studies showing a lack of validation [15].
In order to allow a better comparison of methylation
data, interpretation of the clinical relevance, and, ultim-
ately, implementation of methylation markers into clin-
ical practice, more effort is required to better take into
account the analytical and clinical sensitivity and specifi-
city of a specific assay. A large variety in the quantifica-
tion of methylation signals exists in published DNA
methylation marker studies. For example, variation in
primer location and design and threshold values for de-
termining test positivity affect sensitivity, specificity, and
ultimately the clinical relevance of a biomarker [16, 17].
MSP, pyrosequencing, and methylation-sensitive high-
resolution melting (MS-HRM) are widely used techniques
to assess DNA methylation (Table 1). MSP, developed in
1996 [18], is a sensitive, relatively simple, and inexpensive
technique, which made it an attractive tool to study DNA
methylation in the past decades. MSP is based on PCR
primers, which can distinguish unmethylated and methyl-
ated DNA. The unmethylated primers will only amplify
sodium bisulfite-converted DNA in the unmethylated
condition, while the methylated primers are specific for so-
dium bisulfite-converted methylated DNA. This technology
provides information regarding the methylation status of
the genomic region covered by the MSP primers. However,
suboptimal primer design and optimization of the assay
can lead to non-reproducible results [8, 19, 20], and the
high sensitivity of the technique has led to so-called
false-positive interpretation of results [21]. Uhlmann et
al. first described detection of DNA methylation by
pyrosequencing in 2002 [22]. This technique is based on
the detection of emitted light, which is generated when a
nucleotide gets incorporated in the PCR template by DNA
polymerase, activating an enzymatic cascade. In the pres-
ence of adenosine triphosphate (ATP) sulfurylase, released
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pyrophosphate will be converted to ATP, which in turn is
an energy source for the oxidization of luciferin. This re-
action generates a light signal. The amount of incorpo-
rated nucleotides is proportional to the amount of emitted
light [23, 24]. Due to the difference in DNA sequence of
bisulfite-converted DNA, pyrosequencing enables quanti-
fication of DNA methylation. Wojdacz and Dobrovic were
the first to describe the principle of MS-HRM in 2007
[25]. This technique is based on the detection of a fluores-
cent signal, which is generated by a dye that incorporates
in double-stranded DNA which is released upon melting,
and which can detect single nucleotide differences based
on small deviations in melting temperatures [25]. In order
to study the methylation of a DNA sample, unmethylated
and methylated references have to be included. A differ-
ence in the hydrogen bonds of methylated CpG
dinucleotides and unmethylated CpG dinucleotides results
in a different melting profile with methylated DNA melt-
ing at a higher temperature compared to unmethylated
DNA [26].
Using MSP and pyrosequencing, we recently identified
RET promoter methylation as a possible prognostic
marker for tumor-node-metastasis (TNM classification)
stage II CRC patients. Promoter methylation of RET was
associated with a poorer prognosis in two of three inde-
pendent tissue sample series using both techniques [27].
In this study, we analyze RET promoter CpG island
methylation using four DNA methylation detection
techniques (direct-MSP, nested-MSP, pyrosequencing,
and MS-HRM) and primers aligned as much as possible
regarding the genomic region (Fig. 1), to determine the
influence of the test on the outcome of stage II colon
cancer patients.
Results
Frequency and overlap of promoter CpG island
methylation measured by direct-MSP, nested-MSP,
pyrosequencing, and MS-HRM
Of 209 samples successfully amplified with direct-MSP
primers, 25 samples (12 %) showed RET promoter CpG
island methylation. Using nested-MSP, RET promoter
CpG island was methylated in 71 of 240 (29.6 %) sam-
ples, confirming that nested-MSP is more sensitive than
direct-MSP (Table 2). By pyrosequencing, the frequency
of RET promoter CpG island methylation was dependent
on the threshold for positivity that was used. Using a
threshold for positivity of 20 % (previously defined as
the most optimal threshold for positivity to predict
prognosis in stage II CRC patients using RET methyla-
tion [27]), we detected RET promoter CpG island
methylation in 32 out of 240 (13.3 %) patient samples. In
addition, methylation frequencies were calculated for
thresholds for positivity of 5, 10, 15, and 25 %. As ex-
pected, the higher the methylation threshold for positiv-
ity, the lower was the methylation frequency (Table 2).
Table 1 Characteristics of different methylation analysis
techniques and reported recommendations for assay design
Pyrosequencing MSP MS-HRM
Material FF preferred FFPE/FF FF preferred
Closed-tube √
€/sample 4.76 1.21–1.64b 1.76
Amplicon
length (bp)




























MSP methylation-specific PCR, MS-HRM methylation-sensitive high-resolution
melting, FFPE formalin-fixed paraffin-embedded, FF fresh frozen
aConditions of preamplification PCR (in case of nested-MSP: flank primers)
bDirect-MSP and nested-MSP
Fig. 1 Schematic representation of the RET promoter CpG island (according to the EMBOSS database; located on chromosome 10q11.2) and the
genomic region of primer location. Each rectangle represents a CpG dinucleotide. CpG dinucleotides, which are underlined, point to the primer
locations for all four methylation analysis techniques. Direct-MSP and nested-MSP (here: MSP) share the same primers specific for methylated, as
well as not methylated, DNA. Flanking primers used for nested-MSP amplify bisulfite-treated DNA, without discriminating between methylated
and not methylated DNA. Therefore, these primers are not included in this figure
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RET promoter CpG island methylation detected by
pyrosequencing with a threshold for positivity of 5 %
or higher was observed in 62 out of 240 samples
(25.8 %), whereas a threshold for positivity value of
25 % decreased the methylation frequency to 10.4 %
(25/240). Using MS-HRM, RET promoter CpG island
methylation was observed in 13.8 % of 33 out of 239
samples (Table 2).
Next, we compared the overlap between methylation
analysis techniques. Direct-MSP showed a 100 % con-
cordance with nested-MSP and MS-HRM in that all 25
methylated samples as determined by direct-MSP were
also methylated using nested-MSP and MS-HRM (Fig. 2).
Of these 25 samples, 92 % (n = 23) were also methylated
using pyrosequencing (positivity threshold 20 %). None
of the 209 samples was exclusively detected as methylated
by using direct-MSP. For nested-MSP, the overlap with
direct-MSP (100 % overlap), pyrosequencing (93.8 % over-
lap), and MS-HRM (97 % overlap) was high, although
nested-MSP also detected RET methylation, where direct-
MSP, pyrosequencing, and MS-HRM did not. This was
the case for 63.6 % (42/66), 57.7 % (41/71), and 54.3 %
(38/70) of samples. Out of 71 samples methylated by
nested-MSP, 23 samples (32.4 %) were methylated by all
four methylation analyses techniques (Fig. 2). We ob-
served that pyrosequencing with a threshold for positivity
of 20 % and MS-HRM showed the best overlap. Of the 32
samples methylated by pyrosequencing and 33 by MS-
HRM, 30 samples were methylated by both techniques.
Although nested-MSP and pyrosequencing with a thresh-
old for positivity of 5 % showed comparable methylation
frequencies (29.6 and 25.8 %, respectively), methylation
was not always present in the same samples. Thirty-nine
(54.9 %) out of 71 methylated samples by nested-MSP and
39 (62.9 %) out of 62 methylated samples by pyrosequenc-
ing with a threshold for positivity of 5 % (62.9 %) showed
concordance in RET methylation using these two assays.
Predictive value of RET promoter CpG island methylation
measured by direct-MSP, nested-MSP, pyrosequencing,
and MS-HRM
The high methylation frequency observed by nested-
MSP and pyrosequencing using a low threshold for
positivity is in literature often referred to as a false-
positive detection of methylation. The question re-
mains whether these samples are true false-positive
results or whether these sensitive techniques de-
tected a small amount of RET promoter CpG island


































































MSP methylation-specific PCR, Pyroseq. pyrosequencing, MS-HRM methylation-sensitive high-resolution melting, N number of cases, HR hazard ratio, CI
confidence interval
Fig. 2 Venn diagram showing the overlap between RET methylation detected by direct-MSP (orange), nested-MSP (blue), pyrosequencing (green),
and MS-HRM (purple)
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methylation that is biologically and clinically rele-
vant. Therefore, we calculated the clinical sensitiv-
ities and clinical specificities of each methylation
analysis assay. Moreover, we examined whether dif-
ferent methylation assays influence the predictive
value of RET promoter CpG island methylation.
For direct-MSP, the clinical sensitivity was 10.7 %,
whereas the clinical specificity was 86.5 % (Table 3).
The highest clinical sensitivity with 33.1 % was ob-
served for nested-MSP. This was at the cost of a
lower clinical specificity, as compared to other assays,
which was 73.8 %. As for pyrosequencing, the clinical
sensitivity decreased with a higher threshold for posi-
tivity. For methylation detected using a threshold for
positivity at 20 %, the clinical sensitivity was 14.4 %
and clinical specificity was 87.7 %. Notably, the pyro-
sequencing assay using a 25 % threshold for positivity
showed the highest clinical specificity (90.2 %), as
compared to other assays. The MS-HRM assay de-
tected RET promoter CpG island methylation in de-
ceased patients with a clinical sensitivity of 15.4 %,
whereas the clinical specificity was 87.7 %. For pyro-
sequencing (threshold for positivity at 5 %) on the
other hand, clinical specificity (73.1 %) was similar to
that of nested-MSP (73.8 %); however, the clinical
sensitivity was almost 10 % less than nested-MSP
(22.8 and 33.1 %, respectively). Thus, although both as-
says detect high frequencies of RET methylation, the clin-
ical sensitivity, and thus the ability of detecting patients at
higher risk of dying, is markedly different, however, still
relatively low for both techniques. Subgroup analysis for
gender and sub-location of the tumor does not alter the
conclusions (data not shown).
In order to determine whether the prognostic value
of RET promoter CpG island methylation is affected
by the method of analysis, we performed survival ana-
lyses for each assay. The results of Cox proportional
hazard analyses are summarized in Table 4. While
none of the hazard ratios (HRs) are statistically sig-
nificant in this series of patients, a trend towards a
poorer prognosis with RET methylation can be seen
from the Kaplan-Meier curves (Fig. 3) for nested-MSP
and pyrosequencing (threshold for positivity at 20 %)
as well as MS-HRM. Also, corresponding HRs were
in similar range (HR 1.74, 95 % confidence interval
(CI) 0.97–3.15; HR 1.85, 95 % CI 0.93–3.86; HR 1.83,
95 % CI 0.92–3.65, respectively; Table 4).
Discussion
DNA methylation markers have been recognized as
promising diagnostic, prognostic, and predictive tools
for decades. However, lack of sufficient validation and
evaluation of markers and lack of consensus regarding
the best technique to detect methylation markers
have prevented the introduction of the vast majority
of methylation markers into daily clinical practice. A
variety of DNA methylation analysis techniques have
been developed to analyze genome-wide methylation
and methylation of candidate genes/DNA regions.
Each technology has its own test characteristics,
based on primer and probe design, amplicon size,
PCR conditions (for example, number of amplification
cycles), analytical sensitivity and specificity, and inter-
pretation of results. These differences in test charac-
teristics make it hard to objectively compare the
different methods, which is especially true for tech-
niques that analyze candidate genes/DNA regions.
Recently, RET has been described as a candidate tumor
suppressor gene in CRC, and we have shown that pro-
moter CpG island methylation of RET is associated with
tumorigenesis and a poorer prognosis of CRC patients in
several independent patient populations [27, 28].
Despite the above mentioned challenges in comparing
DNA methylation assays, we set out to compare direct-
MSP, nested-MSP, pyrosequencing, and MS-HRM to
qualitatively and quantitatively analyze RET promoter
CpG island methylation and its predictive value in stage
II colon cancer patients. In order to do this, we aligned
the assays as much as possible regarding the genomic
Table 3 Clinical sensitivity and specificity for methylation
detection using overall survival as end point
Sensitivity (%) Specificity (%)
Direct-MSP 10.7 86.5
Nested-MSP 33.1 73.8
Pyrosequencing 5 % threshold 22.8 73.1
Pyrosequencing 10 % threshold 17.8 83.6
Pyrosequencing 15 % threshold 16.1 85.3
Pyrosequencing 20 % threshold 14.4 87.7
Pyrosequencing 25 % threshold 11.0 90.2
MS-HRM 15.4 87.7
Sensitivity was calculated as a/(a + b). Specificity was calculated as d/(c + d)
MSP methylation-specific PCR, MS-HRM methylation-sensitive
high-resolution melting
Table 4 Baseline characteristics of the study population
Total N (%) 240 (100)
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region, by designing primers for each RET promoter
CpG island methylation assay as close as possible to the
genomic region of the primer sets that have been associ-
ated with the outcome in our previous study [27].
This comparison showed that, as expected, direct-MSP
is less sensitive than nested-MSP and that methylation fre-
quencies detected by pyrosequencing were related to the
threshold for positivity that defined RET methylation. We
also showed that the concordance between the methyla-
tion detection varies between the different techniques
(using the primers as depicted in Fig. 1) and is as low as
54.9 % for nested-MSP versus pyrosequencing (threshold
for positivity at 5 %) and as high as 100 % for direct-MSP
versus nested-MSP. Although methylation detected by
MSP has often been described as a false-positive methyla-
tion, nested-MSP detected RET promoter CpG island
methylation in deceased patients with a higher clinical
sensitivity (33.1 %) when compared to direct-MSP
(10.7 %), pyrosequencing with a threshold of positivity of
20 % (14.4 %), and MS-HRM (15.4 %). Higher thresholds
for positivity to determine methylation for pyrosequencing
showed lower clinical sensitivities, whereas the clinical
specificity was better for quantitative techniques as com-
pared to nested-MSP. We can argue that the clinical spe-
cificity of nested-MSP might indicate an overestimation of
methylation in patients with a good prognosis (RET
methylation 23 %). However, as for pyrosequencing
(threshold for positivity at 20 and 25 %) and MS-HRM,
which showed good clinical specificities and good methy-
lation overlap, the clinical sensitivities also indicate that
those assays still miss a lot of deceased patients. These
data indicate that samples, which were exclusively methyl-
ated by nested-MSP and not by other techniques, should
not solely be considered as false-positive test results.
Nonetheless, it should be kept in mind that nested-MSP
was designed for detection of low levels of DNA methyla-
tion, as, for example, seen in subclones of cancer cells or
tissue with a low amount of tumor cells. The relevance of
Fig. 3 Kaplan-Meier curves of overall survival for three years of follow-up. Patients with RET methylation (red line) measured by direct-MSP
(a), nested-MSP (b), pyrosequencing with a threshold for positivity at 20 % (c), and MS-HRM (d) showed a trend towards a poorer prog-
nosis; however, this was not statistically significant (p > 0.05)
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small amounts of DNA methylation should be carefully
interpreted and can be different between sample sources,
for example, in blood and stool samples versus resection
material. Our data also show that qualitative techniques
such as direct-MSP and nested-MSP (although showing
different methylation frequencies) can, when carefully de-
veloped, optimized, and interpreted, yield comparable
clinical results as pyrosequencing and MS-HRM and
could therefore be used for biomarker detection/valid-
ation. As gel-based assays are not the method of choice
for clinical tests, quantitative techniques, such as closed-
tube techniques, are preferred in clinical settings, which
require the objective establishment of a threshold for posi-
tivity. Unfortunately, such an objective assessment and
clear description of the threshold for positivity is often
lacking in DNA methylation marker studies. Moreover,
quantification of methylation signals is highly dependent
on the percentage of tumor cells in a given specimen.
However, reliable assessment of the tumor cell count is
currently not a standard procedure in clinical settings, and
in addition, the percentage of tumor cells estimated on
hematoxylin and eosin stained slides is often not accurate
[29].
It highly depends on the objective of the study,
whether a high clinical sensitivity or a high clinical
specificity is desired. Using different thresholds for
positivity for pyrosequencing can enable the variation
in assay performance by means of clinical sensitivities
and specificities. This is not possible for nested-MSP
that only allows a yes/no assessment of DNA methy-
lation, which should be kept in mind preceding for-
mulating objectives of a biomarker study. Moreover,
the clinical value of a methylation marker not only
depends on the test characteristics but also on clinical
end points. In the current study, we only had data
available on patient survival. It would be interesting
to correlate the outcome of the different techniques
with the recurrence of disease as end point and to as-
sess comorbidities of these patients, as more than
50 % of CRC patients suffer from comorbidities [29].
RET methylation has previously been described as a
possible prognostic marker for stage II CRC [27]. In the
current study, the prognostic effect of methylation mea-
sured by all assessed techniques was not as evident as in
the previously reported study; however, a trend towards
a poorer prognosis was observed. This was most likely
due to a smaller sample size as compared to the previ-
ous study. We realize that additional molecular or hist-
ology markers should be considered in combination to
RET methylation in order to enhance the predictive
value for accurate and robust identification of high-risk
stage II colon cancer patients or that other markers
might better predict prognosis. Nonetheless, the goal of
this study was not to validate the biomarker potential of
RET methylation but to compare the prognostic value of
RET methylation by comparing four different techniques
to assess methylation. Our results show, for the first
time, that effects on overall survival did not differ des-
pite differences in assays to measure DNA methylation
and differences in clinical sensitivities and specificities.
Conclusions
Due to the high analytic sensitivity of nested-MSP, we were
able to detect more deceased patients (higher clinical sensi-
tivity) than using direct-MSP, pyrosequencing, and MS-
HRM. When selecting methylation assays for biomarker re-
search, the choice of the methylation detection method
highly depends on the objective of the study and if a high
clinical sensitivity or a high clinical specificity is desired.
Methods
Patient samples
We used fresh frozen TNM stage II colon adenocarcin-
oma tissue, which was provided by the Pathology
Department of the academic hospital in Dijon and
which was collected from three pathology laboratories
covering the area: Dijon University Hospital, Compre-
hensive Cancer Centre, and a private center as de-
scribed previously [27, 30]. Baseline characteristics of
this study population are provided in Table 4.
DNA isolation and sodium bisulfite conversion
DNA was isolated using the Nucleospin®96 tissue kit
(Macherey-Nagel, Düren, Germany) as previously de-
scribed [31]. DNA was available for 241 stage II CRC
patients to perform direct-MSP, nested-MSP, pyrose-
quencing, and MS-HRM.
Sodium bisulfite modification of genomic DNA was
performed using the EZ DNA methylation kit (ZYMO
Research Corporation, Orange, CA, USA) according to
the manufacturer’s instructions.
Detection of DNA methylation
In order to compare the test performance of four differ-
ent methylation detection techniques (direct-MSP,
nested-MSP, pyrosequencing, and MS-HRM) for RET
CpG island methylation, we aimed to design the assays
within the same genomic region as close as possible to
each other (Fig. 1). Nevertheless, due to the CpG
dinucleotide-rich region and the technical differences
between the assays, analysis of identical CpG dinucleo-
tides was not always possible. As shown in Fig. 1, direct-
MSP and nested-MSP measure methylation of the CpG
dinucleotides covered by the primers, whereas MS-HRM
detects methylation of CpG dinucleotides in between the
forward and reverse primer as well. As for pyrosequenc-
ing, sequencing primer design is desired without
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covering CpG dinucleotides, while the CpG dinucleo-
tides in between the primers are quantified for
methylation.
Direct-MSP and nested-MSP
In this study, we performed direct-MSP, and the more
sensitive variant, nested-MSP, which has been developed
specifically to amplify DNA obtained from formalin-
fixed, paraffin-embedded tissue [18, 32]. Primer pairs
were designed near the putative transcriptional start site
(TSS; Fig. 1; Additional file 1: Table S1). For nested MSP,
the genomic region of interest is amplified with flanking
primers prior to discriminating with primers specific for
methylated and unmethylated DNA. PCR amplification
data were analyzed by using gel electrophoresis. Of the
241 analyzed samples, direct-MSP did not show a result
for 32/241 (13.3 %) of the samples, whereas for nested-
MSP, one sample (0.4 %) did not show a result.
Pyrosequencing
For the current study, pyrosequencing was performed
as described previously using the PyroMark Q24 kit
(Qiagen, Hilden, Germany) [27]. Briefly, PCR reac-
tions were carried out in a 25 μL final volume com-
prising 12.5 μL of PyroMark Master Mix, 2.5 μL of
CoralLoad buffer, 0.5 μL of forward and biotinylated
reverse primers (0.2 μM final concentration), 8 μL of
RNase-free water, and 1 μL of bisulfite-treated DNA
(20 ng). The biotinylated PCR products were proc-
essed as described elsewhere [31]. Results were ana-
lyzed using PyroMark Q24 2.0.6 software. To ensure
successful bisulfite conversion of unmethylated cyto-
sines, an internal conversion control that corre-
sponded to the position of a non-CG cytosine (not
subject to methylation) was present in the dispensa-
tion sequence. Of the 241 samples analyzed, one sam-
ple (0.4 %) did not show a result. The sequences for
the genomic region of pyrosequencing primers are
provided in Additional file 1: Table S1.
MS-HRM
The MS-HRM assay was designed as close as technic-
ally possible to the genomic region being analyzed by
direct-MSP, nested-MSP, and pyrosequencing assays
(Fig. 1). The sequences for the genomic region of
MS-HRM primers are provided in Additional file 1:
Table S1. By including a CpG dinucleotide in each
primer, we aimed to reduce the possibility of PCR
bias [25]. PCR amplification was carried out in a total
volume of 20 μL of Precision Melt Supermix (Biorad),
250 nM of forward and reverse primer, and 25 ng of
bisulfite-treated DNA template. Amplification was
performed on a LightCycler 96 (Roche) and consisted
of 2 min at 95 °C, followed by 70 cycles of 10 s at
95 °C, 30 s at 56 °C, and 30 s at 72 °C. According to
the manufacturer’s recommendations, HRM analysis
spanned a temperature range from 65–95 °C, with a
ramp rate of 0.04 °C per second and 25 acquisitions.
In each run, a dilution series of 0 (unmethylated
EpiTect Control DNA, Qiagen), 3.125, 6.25, 12.5, 25,
50 (fully methylated templates in fully unmethylated
background), and 100 % (in vitro methylated DNA
(IVD)) was included in order to test the sensitivity of
the assay. Using the LightCycler 96 software, the melting
curves were normalized relative to two normalization
regions before and after the major fluorescence decrease.
The methylation profile was evaluated for each sample by
comparing fluorescence at the melting point against the
value of fluorescence of the negative control (unmethy-
lated DNA). Of the 241 samples analyzed, two samples
(0.8 %) did not show a result.
Data analysis
For direct-MSP and nested-MSP, we considered a sam-
ple as methylated if a clear band for the methylation-
specific amplicon was visible by gel electrophoresis. We
considered a weak methylation-specific amplicon as
methylation positive only if the intensity of the amplicon
was the same as for the amplicon generated with
unmethylated primers. When in doubt, MSPs were re-
peated twice and the result of two out of three MSPs
was considered final. Analyses of pyrosequencing results
are more complex, as different thresholds for positivity
can be defined. For each sample, we calculated the mean
methylation percentage for six analyzed CpG dinucleo-
tides. As we were interested in the effect of different
thresholds for positivity, we analyzed our results with
thresholds for positivity at 5, 10, 15, 20, and 25 %. MS-
HRM has no single CpG dinucleotide resolution, and
therefore, percentages of methylation cannot directly be
converted from the melting curves. Therefore, within
each assay run, we included a dilution series of controls
with theoretically different methylation rates (unmethy-
lated, 3.125, 6.25, 12.5, 25, and 50 % methylated and
fully methylated DNA). Using the melting profile of the
dilution series, we considered a sample as methylated if
the melting curve deviated as the curve of the 3.125 %
dilution or higher.
The RET promoter CpG island methylation frequency
was presented for direct-MSP, nested-MSP, pyrosequenc-
ing, and MS-HRM as a percentage: the number of methyl-
ated samples divided by number of successfully amplified
samples. In addition, for each assay, the overlap of methy-
lation between techniques was determined. Therefore, we
used the total number of methylated samples by direct-
MSP, nested-MSP, pyrosequencing, and MS-HRM and
compared them in a 2 × 2 table using SPSS.
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To compare the clinical sensitivity and specificity of
direct-MSP, nested-MSP, pyrosequencing, and MS-
HRM, we computed clinical sensitivities and clinical
specificities among deceased patients and subjects still
alive, respectively, using overall mortality for the total
follow-up period of up to 8 years as the standard. Clin-
ical sensitivities and specificities were calculated for all
assays as follows: we defined in the deceased patient
group, the number of subjects (a) where the test was
positive (true-positive) or (b) negative (false-negative) as
well as the number of patients who are still alive but
where the test was positive (c, false-positive) or negative
(d, true-negative), using the formulas a/(a + b) and d/(c
+ d), respectively.
For survival analysis, overall survival (OS) was defined
as time from cancer diagnosis until death of all causes.
Three- and five-year survival analyses were performed
for each methylation technique. Kaplan-Meier curves
and log-rank tests were used to estimate the influence of
methylation on overall survival. Hazard ratios (HR) and
corresponding 95 % confidence intervals (CIs) were esti-
mated using an unadjusted Cox proportional hazard
model as previously described [27].
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